Pacific Biosciences of California, Inc. Revenue
Pacific Biosciences of California, Inc. (PACB) reported Revenue of $39.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $39.01M, a 1.91% decline year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $37.18M, a 0.07% increase year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $38.44M, a 3.82% decline year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $39.77M, a 10.42% increase year-over-year.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $78.63M, a 15.88% decline from fiscal 2017.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2017 was $93.47M, a 3.04% increase from fiscal 2016.
- Pacific Biosciences of California, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2016 was $90.71M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $39.01M 10-Q · filed 2026-08-06 | $76.19M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $37.18M 10-Q · filed 2026-05-08 | ||||
| 2025-09-30 | $38.44M 10-Q · filed 2025-11-06 | $78.21M derived: sum of 2 quarters · filed 2026-08-06 | $115.36M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $39.77M 10-Q · filed 2026-08-06 | $76.92M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $37.15M 10-Q · filed 2026-05-08 | ||||
| 2024-09-30 | $39.97M 10-Q · filed 2025-11-06 | $75.98M derived: sum of 2 quarters · filed 2025-11-06 | $114.79M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $36.01M 10-Q · filed 2025-08-07 | $74.82M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $38.81M 10-Q · filed 2025-05-12 | ||||
| 2023-09-30 | $55.69M 10-Q · filed 2024-11-12 | $103.26M derived: sum of 2 quarters · filed 2024-11-12 | $142.16M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $47.57M 10-Q · filed 2024-08-09 | $86.47M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $38.90M 10-Q · filed 2024-05-09 | ||||
| 2022-09-30 | $32.31M 10-Q · filed 2023-11-03 | $67.78M derived: sum of 2 quarters · filed 2023-11-03 | $100.95M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $35.47M 10-Q · filed 2023-08-04 | $68.64M 10-Q · filed 2023-08-04 | |||
| 2022-03-31 | $33.17M 10-Q · filed 2023-05-04 | ||||
| 2021-09-30 | $34.89M 10-Q · filed 2022-11-08 | $65.50M derived: sum of 2 quarters · filed 2022-11-08 | $94.49M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $30.61M 10-Q · filed 2022-08-08 | $59.61M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $29.00M 10-Q · filed 2022-05-06 | ||||
| 2020-09-30 | $19.08M 10-Q · filed 2021-11-05 | $38.16M derived: sum of 2 quarters · filed 2021-11-05 | $51.76M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $19.08M 10-Q · filed 2021-11-05 | $17.08M 10-Q · filed 2020-08-06 | $32.67M 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $15.60M 10-Q · filed 2021-05-06 | ||||
| 2019-09-30 | $21.91M 10-Q · filed 2020-11-03 | $46.54M derived: sum of 2 quarters · filed 2020-11-03 | $62.96M 10-Q · filed 2020-11-03 | $82.49M derived: sum of 4 quarters · filed 2020-11-03 | |
| 2019-06-30 | $24.62M 10-Q · filed 2020-08-06 | $41.05M 10-Q · filed 2020-08-06 | $60.57M derived: sum of 3 quarters · filed 2020-08-06 | $78.73M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $16.43M 10-Q · filed 2020-05-08 | $35.95M derived: sum of 2 quarters · filed 2020-05-08 | $54.11M derived: sum of 3 quarters · filed 2020-05-08 | $75.69M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $19.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $37.69M derived: sum of 2 quarters · filed 2019-11-07 | $59.26M derived: sum of 3 quarters · filed 2019-11-07 | $78.63M 10-K · filed 2019-02-26 | |
| 2018-09-30 | $18.16M 10-Q · filed 2019-11-07 | $39.74M derived: sum of 2 quarters · filed 2019-11-07 | $59.10M 10-Q · filed 2019-11-07 | $84.03M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $21.58M 10-Q · filed 2019-08-06 | $40.94M 10-Q · filed 2019-08-06 | $65.88M derived: sum of 3 quarters · filed 2019-08-06 | $89.42M derived: sum of 4 quarters · filed 2019-08-06 | |
| 2018-03-31 | $19.36M 10-Q · filed 2019-05-03 | $44.30M derived: sum of 2 quarters · filed 2019-05-03 | $67.84M derived: sum of 3 quarters · filed 2019-05-03 | $87.92M derived: sum of 4 quarters · filed 2019-05-03 | |
| 2017-12-31 | $24.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $48.48M derived: sum of 2 quarters · filed 2019-02-26 | $68.55M derived: sum of 3 quarters · filed 2019-02-26 | $93.47M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $23.55M 10-Q · filed 2018-11-05 | $43.62M derived: sum of 2 quarters · filed 2018-11-05 | $68.53M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $20.07M 10-Q · filed 2018-08-03 | $44.99M 10-Q · filed 2018-08-03 | |||
| 2017-03-31 | $24.91M 10-Q · filed 2018-05-02 | ||||
| 2016-12-31 | $90.71M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |